Ascentage Pharma to Present at the 36th Annual J.P. Morgan Healthcare Conference

ROCKVILLE, MD and HONG KONG, CHINA /PRNewswire/ – Ascentage Pharma, a global clinical-stage biopharmaceutical company dedicated to developing apoptosis-targeted therapies for cancers and other diseases, today announced that Dajun Yang, M.D., Ph.D., the Company’s Chairman & Chief Executive Officer, will present a corporate overview at the 36th Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 8:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California, USA.

About Ascentage Pharma

Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and aging-related diseases. Based on breakthrough technology from the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visitwww.ascentagepharma.com.